Nkarta (NKTX) Competitors $1.76 +0.02 (+0.86%) Closing price 07/3/2025 03:55 PM EasternExtended Trading$1.76 0.00 (0.00%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKTX vs. ABVX, SEPN, ORGO, SIGA, CGEM, ATYR, KMDA, ATAI, TRML, and MREOShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Abivax (ABVX), Septerna (SEPN), Organogenesis (ORGO), Siga Technologies (SIGA), Cullinan Therapeutics (CGEM), aTyr Pharma (ATYR), Kamada (KMDA), atai Life Sciences (ATAI), Tourmaline Bio (TRML), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Its Competitors Abivax Septerna Organogenesis Siga Technologies Cullinan Therapeutics aTyr Pharma Kamada atai Life Sciences Tourmaline Bio Mereo BioPharma Group Abivax (NASDAQ:ABVX) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations. Is ABVX or NKTX more profitable? Abivax's return on equity of 0.00% beat Nkarta's return on equity.Company Net Margins Return on Equity Return on Assets AbivaxN/A N/A N/A Nkarta N/A -26.64%-21.62% Do insiders and institutionals have more ownership in ABVX or NKTX? 47.9% of Abivax shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 8.4% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation and earnings, ABVX or NKTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbivaxN/AN/A-$190.71MN/AN/ANkartaN/AN/A-$108.79M-$1.51-1.16 Does the media prefer ABVX or NKTX? In the previous week, Nkarta had 2 more articles in the media than Abivax. MarketBeat recorded 3 mentions for Nkarta and 1 mentions for Abivax. Abivax's average media sentiment score of 1.19 beat Nkarta's score of 0.45 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ABVX or NKTX? Abivax presently has a consensus target price of $31.00, suggesting a potential upside of 288.96%. Nkarta has a consensus target price of $14.33, suggesting a potential upside of 716.71%. Given Nkarta's stronger consensus rating and higher possible upside, analysts plainly believe Nkarta is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abivax 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Nkarta 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13 Which has more volatility & risk, ABVX or NKTX? Abivax has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. SummaryNkarta beats Abivax on 9 of the 12 factors compared between the two stocks. Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$124.18M$2.92B$5.55B$9.05BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-1.1621.5627.6120.23Price / SalesN/A278.31417.23118.52Price / CashN/A42.7336.8958.10Price / Book0.307.518.035.67Net Income-$108.79M-$55.14M$3.18B$249.21M7 Day Performance5.72%4.61%2.93%3.28%1 Month Performance-4.10%4.72%3.75%5.55%1 Year Performance-66.12%5.92%35.20%21.09% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta2.2945 of 5 stars$1.76+0.9%$14.33+716.7%-67.2%$124.18MN/A-1.16140ABVXAbivax2.407 of 5 stars$7.65+3.4%$31.00+305.2%-39.0%$469.56MN/A0.0061News CoveragePositive NewsGap UpHigh Trading VolumeSEPNSepterna1.1247 of 5 stars$10.57+0.6%$26.75+153.1%N/A$468.31M$1.08M0.00N/AORGOOrganogenesis4.0859 of 5 stars$3.66-0.3%$6.00+63.9%+55.9%$465.55M$482.04M-21.53950News CoverageSIGASiga Technologies0.9007 of 5 stars$6.52+0.9%N/A-13.0%$461.51M$138.72M9.7340CGEMCullinan Therapeutics1.5189 of 5 stars$7.53-3.0%$30.00+298.4%-53.5%$457.95MN/A-2.5930Positive NewsATYRaTyr Pharma2.6269 of 5 stars$5.07+0.8%$20.20+298.4%N/A$447.69M$230K-6.2653High Trading VolumeKMDAKamada3.9326 of 5 stars$7.75+0.5%$14.67+89.2%+50.6%$443.36M$160.95M26.72360News CoverageATAIatai Life Sciences2.9812 of 5 stars$2.19-0.5%$8.67+295.7%+116.8%$440.74M$310K-2.4180Analyst ForecastOptions VolumeTRMLTourmaline Bio2.1311 of 5 stars$15.99-3.3%$49.33+208.5%+30.7%$424.84MN/A-4.9844MREOMereo BioPharma Group1.7987 of 5 stars$2.71+1.9%$7.60+180.4%-19.9%$422.94M$10M-38.7140 Related Companies and Tools Related Companies Abivax Competitors Septerna Competitors Organogenesis Competitors Siga Technologies Competitors Cullinan Therapeutics Competitors aTyr Pharma Competitors Kamada Competitors atai Life Sciences Competitors Tourmaline Bio Competitors Mereo BioPharma Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NKTX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKTX Stock Alerts